OCULAR THERAPEUTIX, INC (OCUL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q4 '14: 772K Q1 '15: 1.2M Q2 '15: 1.5M Q3 '15: 1.8M Q4 '15: 1.8M Q1 '16: 1.8M Q2 '16: 1.8M Q1 '17: 1.9M Q2 '17: 1.9M Q3 '17: 1.9M Q4 '17: 1.9M Q1 '18: 1.8M Q2 '18: 2M Q3 '18: 2M Q4 '18: 2M Q1 '19: 2.1M Q2 '19: 2.1M Q3 '19: 2.5M Q4 '19: 4.2M Q1 '20: 6.3M Q2 '20: 7.3M Q3 '20: 12.3M Q4 '20: 17.4M Q1 '21: 22.1M Q2 '21: 32.3M Q3 '21: 38.6M Q4 '21: 43.5M Q1 '22: 49.4M Q2 '22: 49.9M Q3 '22: 49.7M Q4 '22: 51.5M Q1 '23: 51.7M Q2 '23: 54.6M Q3 '23: 57.7M Q4 '23: 58.4M Q1 '24: 59.8M Q2 '24: 61.1M Q3 '24: 61.4M Q4 '24: 63.7M Q1 '25: 59.6M Q2 '25: 56.7M Q3 '25: 55.8M Q4 '25: 52M Q1 '26: 52M Q2 '26: 52.1M Q2 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Gross Profit TTM

0 20M 40M 60M Q4 '18: 1.5M Q1 '19: 1.6M Q2 '19: 1.2M Q3 '19: 872K Q4 '19: 1.9M Q1 '20: 3.3M Q2 '20: 4.7M Q3 '20: 10.1M Q4 '20: 15.3M Q1 '21: 20M Q2 '21: 29.2M Q3 '21: 34.6M Q4 '21: 39.1M Q1 '22: 44.6M Q2 '22: 45M Q3 '22: 45.1M Q4 '22: 47M Q1 '23: 47.2M Q2 '23: 50M Q3 '23: 52.8M Q4 '23: 53.2M Q1 '24: 54.4M Q2 '24: 55.5M Q3 '24: 55.7M Q4 '24: 58.1M Q1 '25: 54.1M Q2 '25: 50.7M Q3 '25: 49.6M Q4 '25: 45.4M Q1 '26: 45.4M Q2 '26: 45.3M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '13: -12.9M Q1 '14: -16.7M Q2 '14: -19.6M Q3 '14: -23M Q4 '14: -27.1M Q1 '15: -27.4M Q2 '15: -31.1M Q3 '15: -35.5M Q4 '15: -38.2M Q1 '16: -41.6M Q2 '16: -43.1M Q1 '17: -48.5M Q2 '17: -55.7M Q3 '17: -61.7M Q4 '17: -61.9M Q1 '18: -59.7M Q2 '18: -54.9M Q3 '18: -54.6M Q4 '18: -59.1M Q1 '19: -65.3M Q2 '19: -73.4M Q3 '19: -81.7M Q4 '19: -85.8M Q1 '20: -82.8M Q2 '20: -79M Q3 '20: -69.9M Q4 '20: -62.8M Q1 '21: -66.5M Q2 '21: -68.8M Q3 '21: -74.3M Q4 '21: -78M Q1 '22: -75.6M Q2 '22: -75.3M Q3 '22: -77.3M Q4 '22: -78.7M Q1 '23: -83.4M Q2 '23: -84M Q3 '23: -81.7M Q4 '23: -82.4M Q1 '24: -91.5M Q2 '24: -114.5M Q3 '24: -141.3M Q4 '24: -171.8M Q1 '25: -204.1M Q2 '25: -228.1M Q3 '25: -250.8M Q4 '25: -270M Q1 '26: -299.4M Q2 '26: -313.9M Q2 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '13: -13.3M Q1 '14: -17.1M Q2 '14: -20.4M Q3 '14: -24.2M Q4 '14: -28.6M Q1 '15: -29.2M Q2 '15: -32.8M Q3 '15: -37.1M Q4 '15: -39.7M Q1 '16: -43M Q2 '16: -44.4M Q1 '17: -49.9M Q2 '17: -57.1M Q3 '17: -63.1M Q4 '17: -63.4M Q1 '18: -61.1M Q2 '18: -56.2M Q3 '18: -55.7M Q4 '18: -60M Q1 '19: -63.3M Q2 '19: -74M Q3 '19: -77.8M Q4 '19: -86.4M Q1 '20: -90.8M Q2 '20: -102.9M Q3 '20: -96M Q4 '20: -155.6M Q1 '21: -131M Q2 '21: -102.9M Q3 '21: -88.3M Q4 '21: -6.6M Q1 '22: -22.2M Q2 '22: -32.5M Q3 '22: -59.3M Q4 '22: -71M Q1 '23: -88.8M Q2 '23: -90.7M Q3 '23: -67.1M Q4 '23: -80.7M Q1 '24: -115.3M Q2 '24: -138.4M Q3 '24: -174.3M Q4 '24: -193.5M Q1 '25: -192.7M Q2 '25: -216.7M Q3 '25: -249.7M Q4 '25: -265.9M Q1 '26: -290.5M Q2 '26: -301.4M Q2 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue TTM

0 2.5M 5M 7.5M Q4 '18: 465K Q1 '19: 513K Q2 '19: 912K Q3 '19: 1.6M Q4 '19: 2.3M Q1 '20: 3M Q2 '20: 2.6M Q3 '20: 2.2M Q4 '20: 2.1M Q1 '21: 2.2M Q2 '21: 3.1M Q3 '21: 4M Q4 '21: 4.4M Q1 '22: 4.8M Q2 '22: 4.9M Q3 '22: 4.6M Q4 '22: 4.5M Q1 '23: 4.5M Q2 '23: 4.6M Q3 '23: 4.9M Q4 '23: 5.3M Q1 '24: 5.4M Q2 '24: 5.6M Q3 '24: 5.8M Q4 '24: 5.6M Q1 '25: 5.6M Q2 '25: 6M Q3 '25: 6.2M Q4 '25: 6.6M Q1 '26: 6.6M Q2 '26: 6.7M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '14: -14.8M Q3 '14: -18.3M Q4 '14: -20.5M Q1 '15: -23.4M Q2 '15: -27.4M Q3 '15: -30.7M Q4 '15: -33.7M Q1 '16: -36.1M Q2 '16: -37.4M Q3 '16: -35M Q4 '16: -34M Q1 '17: -39.3M Q2 '17: -40.7M Q3 '17: -47.7M Q4 '17: -50.5M Q1 '18: -48.4M Q2 '18: -49.5M Q3 '18: -46M Q4 '18: -49.2M Q1 '19: -56.1M Q2 '19: -63.1M Q3 '19: -71.8M Q4 '19: -77.6M Q1 '20: -77M Q2 '20: -72.7M Q3 '20: -66.8M Q4 '20: -53.6M Q1 '21: -52.1M Q2 '21: -57.3M Q3 '21: -56.6M Q4 '21: -65.5M Q1 '22: -66.8M Q2 '22: -57.6M Q3 '22: -57.8M Q4 '22: -59.6M Q1 '23: -61M Q2 '23: -70.2M Q3 '23: -64.7M Q4 '23: -70.2M Q1 '24: -84.1M Q2 '24: -88.9M Q3 '24: -117.7M Q4 '24: -134.7M Q1 '25: -145.5M Q2 '25: -175.9M Q3 '25: -190.1M Q4 '25: -204.9M Q1 '26: -226.2M Q2 '26: -238.2M Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '14: -15.7M Q3 '14: -19.4M Q4 '14: -21.8M Q1 '15: -24.7M Q2 '15: -29.3M Q3 '15: -32.5M Q4 '15: -35.5M Q1 '16: -37.7M Q2 '16: -38.3M Q3 '16: -36.7M Q4 '16: -35.9M Q1 '17: -42.8M Q2 '17: -47.9M Q3 '17: -56.1M Q4 '17: -58.7M Q1 '18: -55.3M Q2 '18: -53M Q3 '18: -47.9M Q4 '18: -51.1M Q1 '19: -58.4M Q2 '19: -65.3M Q3 '19: -73.9M Q4 '19: -79.8M Q1 '20: -78.8M Q2 '20: -74.1M Q3 '20: -68M Q4 '20: -54.4M Q1 '21: -52.8M Q2 '21: -58.1M Q3 '21: -57.5M Q4 '21: -66.7M Q1 '22: -68.1M Q2 '22: -59.3M Q3 '22: -60M Q4 '22: -63.3M Q1 '23: -67.8M Q2 '23: -78.5M Q3 '23: -72.5M Q4 '23: -76.3M Q1 '24: -87.1M Q2 '24: -90.6M Q3 '24: -119.2M Q4 '24: -136M Q1 '25: -148.4M Q2 '25: -179.4M Q3 '25: -199.4M Q4 '25: -216.9M Q1 '26: -240.9M Q2 '26: -255.1M Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q1 '18: 34.8M Q3 '18: 39M Q1 '19: 44.2M Q3 '19: 52.7M Q1 '20: 51.9M Q2 '20: 57.4M Q3 '20: 68.8M Q1 '21: 87.2M Q2 '21: 82.1M Q3 '21: 85.4M Q1 '22: 82.5M Q2 '22: 82.5M Q3 '22: 77M Q1 '23: 77.4M Q2 '23: 78M Q3 '23: 85.1M Q1 '24: 132M Q2 '24: 165.8M Q3 '24: 167M Q1 '25: 169.4M Q2 '25: 172.6M Q3 '25: 183.9M Q1 '26: 224.1M Q2 '26: 225M Q1 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '13: -5.11 Q1 '14: -6.30 Q2 '14: -7.21 Q3 '14: -6.35 Q4 '14: -5.40 Q1 '15: -3.30 Q2 '15: -1.65 Q3 '15: -1.64 Q4 '15: -1.70 Q1 '16: -1.79 Q2 '16: -1.80 Q1 '17: -1.95 Q2 '17: -2.13 Q3 '17: -2.28 Q4 '17: -2.20 Q1 '18: -2.02 Q2 '18: -1.75 Q3 '18: -1.59 Q4 '18: -1.57 Q1 '19: -1.62 Q2 '19: -1.82 Q3 '19: -1.89 Q4 '19: -2.00 Q1 '20: -1.96 Q2 '20: -2.03 Q3 '20: -1.79 Q4 '20: -2.60 Q3 '22: -1.01 Q4 '22: -1.02 Q1 '23: -1.19 Q2 '23: -1.20 Q3 '24: -1.22 Q4 '24: -1.25 Q1 '25: -1.14 Q2 '25: -1.27 Q3 '25: -1.43 Q4 '25: -1.42 Q1 '26: -1.44 Q2 '26: -1.40 Q3 '14 Q4 '15 Q3 '17 Q4 '18 Q1 '20 Q4 '22 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.